Objective: We determined if the epidermal growth factor receptor ligand HB-EGF is produced in cartilage and if it regulates chondrocyte anabolic or catabolic activity. Methods: HB-EGF expression was measured by quantitative PCR using RNA isolated from mouse knee joint tissues and from normal and osteoarthritis (OA) human chondrocytes. Immunohistochemistry was performed on normal and OA human cartilage and meniscus sections. Cultured chondrocytes were treated with fibronectin fragments (FN-f) as a catabolic stimulus and osteogenic protein 1 (OP-1) as an anabolic stimulus. Effects of HB-EGF on cell signaling were analyzed by immunoblotting of selected signaling proteins. MMP-13 was measured in conditioned media, proteoglycan synthesis was measured by sulfate incorporation, and matrix gene expression by quantitative PCR. Results: HB-EGF expression was increased in 12-month old mice at 8 weeks after surgery to induce OA and increased amounts of HB-EGF were noted in human articular cartilage from OA knees. FN-f stimulated chondrocyte HB-EGF expression and HB-EGF stimulated chondrocyte MMP-13 production. However, HB-EGF was not required for FN-f stimulation of MMP-13 production. HB-EGF activated the ERK and p38 MAP kinases and stimulated phosphorylation of Smad1 at an inhibitory serine site which was associated with inhibition of OP-1 mediated proteoglycan synthesis and reduced aggrecan (ACAN) but not COL2A1 expression. Conclusion: HB-EGF is a new factor identified in OA cartilage that promotes chondrocyte catabolic activity while inhibiting anabolic activity suggesting it could contribute to the catabolic-anabolic imbalance seen in OA cartilage.
Introduction
The progressive degradation and loss of articular cartilage during the development of osteoarthritis (OA) is thought to be due to an imbalance in chondrocyte anabolic and catabolic activity 1 . An important goal of OA research has been to identify the factors that promote catabolic over anabolic activity with the hope that one or more of these mediators might serve as a therapeutic target. A host of soluble mediators capable of regulating chondrocyte activity have been found to be produced locally by the articular chondrocytes and act in an autocrine and paracrine fashion. These include various growth factors, cytokines, chemokines, Wnt family members, and toll-like receptor agonists, to name just a few. It is also well recognized that these and other factors produced by neighboring joint tissues, including the synovium, subchondral bone, and the menisci in the knee, can also regulate chondrocyte activity to promote catabolic over anabolic activity 2 . Despite the number of factors identified to date, it is not known which mediators would be the best targets for therapy and if other mediators not yet studied may also be involved.
In an attempt to discover novel biological mediators that could contribute to OA, we recently performed a computational analysis of gene expression microarray data generated using RNA isolated from knee joint tissues during a time course experiment in mice 3 . OA was induced using the destabilized medial meniscus (DMM) model and RNA was isolated from knee joint tissues at baseline, 2, 4, 8, and 16 weeks after surgery. We focused on signaling and metabolic pathways and found a subnetwork, significantly regulated during the development of OA, that included a potential proteineprotein interaction link between matrix metalloproteinase (MMP)-2 and the epidermal growth factor receptor (EGFR) via heparin-binding epidermal growth factor-like growth factor (HB-EGF).
There is very little data on HB-EGF in joint tissues with one study showing a 2.76-fold difference in HBEGF gene expression in damaged relative to intact cartilage obtained at the time of joint replacement surgery for knee OA 4 . HB-EGF can serve as a ligand for the EGFR and activation of the chondrocyte EGFR by transforming growth-factora (TGFa) has been shown to stimulate MMP expression and cartilage degradation as well as inhibit Sox-9 expression and anabolic activity 5, 6 . We postulated that HB-EGF could be another mediator that promotes catabolic over anabolic activity in cartilage. Therefore, the objective of the present study was to investigate HB-EGF expression and production in normal and OA cartilage and determine its effects on chondrocyte catabolic and anabolic activity.
Methods

Reagents
Phospho-ERK, phospho-p38, phospho-Smad1 ser206 , phospho-Smad1 ser463/465 /Smad5 ser463/465 /Smad8 ser465/467 , total Smad1, total p38, and total ERK antibodies were from Cell Signaling (Beverly, MA). MMP-13 antibody was from Abcam (Cambridge, MA). HB-EGF antibody, HB-EGF ELISA duoset, MMP-13 ELISA, EGF receptor inhibitor AG1478, ERK inhibitor U0126, and recombinant HB-EGF were from R&D Systems (Minneapolis, MN). P38 inhibitor SB203580 and MMP-2 antibody were from EMD Millipore (Billerica, MA). Control siRNA and smartpool siRNA against HB-EGF were from Dharmacon (Lafayette, CO). Amaxa nucleofection reagents for transfection were from Lonza (Walkersville, MD). Predesigned MMP-13, HB-EGF, COL2A1, ID1, SMAD6, TGFa, and a5 integrin (ITGA5) real-time PCR primers were from SuperArray Biosciences (Frederick, MD). Primers for TBP, B2M, and ACAN were from the Wake Forest School of Medicine DNA laboratory. Sequences for these are provided in Table S1 . AMV Reverse Transcriptase and RT 2 SYBR ® green ROX™ qPCR Mastermix were purchased from Promega and Qiagen, respectively. Recombinant fibronectin fragment containing the RGD cell binding domain was produced using an expression construct provided by Dr Harold Erickson (Duke University, Durham, NC). Vectastain Elite ABC kit and Nova Red substrate were from Vector Labs (Burlingame, CA). PicoGreen DNA assay was from Invitrogen (Carlsbad, CA). Mayer's Hematoxylin was from Sigma (St. Louis, MO).
Tissue acquisition and chondrocyte isolation
Normal human ankle articular cartilage was obtained from deceased tissue donors with no known history of arthritis from the Gift of Hope Organ and Tissue Donor Network (Itasca, IL) through the Department of Biochemistry at Rush University Medical Center (Chicago, IL). Tissue from a total of 35 individual donors with ages from 46 to 77 years (avg 64 years) was used for cell culture studies. Chondrocytes were isolated with sequential pronase and collagenase digestion and plated at high density monolayer as previously described 7 . All cells were used without passaging to ensure proper phenotype was retained.
Immunohistochemistry
Cartilage and medial meniscal sections used for immunohistochemistry were from young normal (n ¼ 4, ages 36e48), old normal (n ¼ 4, ages 68e76) and OA (n ¼ 4, ages 64e90) donors and were a kind gift of Dr Martin Lotz (Scripps Research Institute, La Jolla, CA). Although the current study focused on HB-EGF in cartilage, we examined HB-EGF levels in the meniscus as a comparison to cartilage, in particular because the outer region of the meniscus contains blood vessels which would be expected to contain HB-EGF and could serve as a positive immunostaining control. The sections embedded in paraffin were deparaffinized followed by staining with Vectastain Elite Kit (Vector Labs) according to manufacturer's instructions. Tissue was incubated overnight at 4 C with a 10 mg/mL goat anti-HBEGF antibody. Tissue incubated with no primary antibody was used as a negative control. Staining was visualized with ImmPACT Nova Red substrate (Vector Labs). Nuclei were visualized by Mayer's Hematoxylin staining. Images were captured using the indicated objectives.
Quantitative real-time PCR
The RNA used for measuring HB-EGF expression in the DMM model of OA was from a previously published microarray study 8 . RNA from sham control and DMM knees joints was subjected to real-time PCR analysis using predesigned primers specific for mouse HB-EGF. HB-EGF levels were normalized to the expression of TATA box-binding protein measured in parallel samples. For studies using isolated human chondrocytes, RNA was isolated from confluent monolayers using TRIzol and primers specific for human HB-EGF were used. RNA isolation and real-time PCR were performed as previously described 9 . RNA was also isolated directly from frozen samples of articular cartilage obtained from normal tissue donors (n ¼ 7, mean age 53 years) and OA (n ¼ 5, mean age 57 years) patients who had undergone knee arthroplasty. For this, the tissue was first ground to a powder using the BioPulverizer system (BioSpec Products, Inc. #59012MS) which was pre-chilled in liquid nitrogen. 50e100 mg of cartilage powder from each sample was further homogenized in 2 ml of TRIzol using a 3 ml syringe with an 18G needle. RNA was isolated from the aqueous phase after Chloroform separation. Following isopropanol precipitation and 70% ethanol washes, the resulted RNA pellet was dissolved in 100 ml of dH 2 O followed by a cleanup step using the RNeasy Mini Kit (Qiagen). RNA concentration was measured using the NanoDrop 2000 (Thermo Scientific) and quality was verified using the Agilent Technologies 2200 TapeStation. 600 ng total RNA per sample was then converted to cDNA using AMV Reverse Transcriptase (Promega). The resulted cDNA was diluted 4 times and analyzed by realtime PCR using the Bio-Rad CFX96 Real-Time System and CFX manager analysis software.
Immunoblotting
Conditioned media and cell lysates were collected and used for immunoblotting as previously described 7 . Primary antibodies were diluted to 1:1000 and immunoreactive bands were detected using chemiluminescence. All immunoblotting experiments were repeated at least 3 times with cells from different donors. For analysis of HB-EGF levels in conditioned media in response to fibronectin fragment (FN-f), we stripped and probed for MMP-2 as a control which in previous studies we had found did not change with FN-f treatment 10 .
Chondrocyte transfection
Chondrocytes were transfected by the nucleofection method, using a human chondrocyte nucleofection kit (Lonza) as described previously 11 . Briefly, 2 million isolated cells were resuspended in transfection reagent and nucleofected with 1000 nm of siRNA for HB-EGF or control nontargeting siRNA. After the recovery period of 48 h, cells were made serum-free overnight before stimulation.
Proteoglycan synthesis assay
The [ 35 S]sulfate incorporation assay was performed to measure proteoglycan synthesis. Chondrocytes were cultured in serum-free medium in monolayer for overnight stimulation using 100 ng/mL OP-1 with or without 10 ng/mL HB-EGF. The next day the medium was replaced with fresh serum-free medium 1 h prior to incubation with [ 35 S]sulfate for another 4 h [ 35 S]sulfate incorporation was measured using the Alcian blue precipitation method and normalized to DNA content 9 . DNA was quantitated by PicoGreen double-stranded DNA assay according to the manufacturer's protocol.
Statistical analysis
Each experiment was performed at least three times with cells from independent tissue donors for normal tissue and independent OA knee joint tissues for OA. The number of independent samples used for each experiment is provided in the figure legends and the total number of independent samples used for cell culture, immunohistochemistry, and RNA isolation are provided in the respective sections of the methods above. Statistical analysis was performed using Statview software (SAS Institute) or with Prism 6 (GraphPad). Results were analyzed by analysis of variance (ANOVA) and Fisher's PLSD (Statview) or Tukey's test (Prism) for post hoc testing. 
Results
HB-EGF is increased in mouse and human OA knee joints
A recent gene microarray study from our group revealed that heparin-binding EGF-like growth factor (HB-EGF) was up-regulated following DMM surgery in knee joint tissue from both 12 week-old and 12 month-old mice 8 . In that study, the histological scores for OA in the older group of mice were twice that of the young which was accompanied by significant differences in gene expression related to both age and OA. To confirm the HB-EGF results on the gene array, we subjected samples from the same study to real-time PCR analysis for HB-EGF expression. HB-EGF was increased at 8 weeks after DMM surgery in the 12 week-old animals (þ39%) relative to 12 week-old sham controls, although the difference was not significant (P ¼ 0.11). However, HB-EGF expression was~494% greater in the 12 month-old DMM animals relative to age-matched sham controls (P < 0.001; Fig. 1(A) ).
We next determined if we could detect HB-EGF protein in adult human cartilage. Sections of human tibial plateaus from both normal donors and OA joints were subjected to immunohistochemical staining with anti-HB-EGF antibody. HB-EGF immunostaining was increased in OA cartilage relative to normal and was mainly localized to cells [ Fig. 1(B) ]. We did not see any significant differences when comparing normal cartilage sections from young and older adults. We also examined meniscal tissue from the same joints and noted strong HB-EGF immunostaining in both cells, particularly in blood vessels (where HB-EGF would be expected), and diffusely in the matrix [ Fig. 1(B) ]. There was no apparent difference between menisci from normal and OA joints (Supplemental Fig. 1(S) ). HB-EGF expression in cartilage was further investigated using RNA isolated directly from normal and OA human cartilage that was matched for age (avg age 53.1 years for normal and 57.4 years for OA). The levels of HB-EGF were on average 2-fold higher in RNA from OA cartilage [ Fig. 1(C) ]. 
HB-EGF expression and secretion are increased by catabolic stimulation of normal human chondrocytes
Since HB-EGF was found at increased levels in OA tissue, we examined if a catabolic stimulus would increase chondrocyte expression of HB-EGF. We chose to use recombinant fibronectin fragments (FN-f) as a model for catabolic stimulation of chondrocytes. FN-f are found at increased levels in OA tissue 12, 13 and stimulate chondrocyte and meniscal cell catabolic signaling that results in increased production of cytokines, chemokines and MMPs that are relevant to OA 11, 14, 15 . In time course experiments from 30 min to 6 h, FN-f increased chondrocyte HB-EGF expression that peaked at 3 h [ Fig. 2(A) ]. We also examined expression of TGFa which, like HB-EGF, serves as a ligand for the EGF receptor. We did not find a significant increase in TGFa in response to FN-f although we did detect a significant increase in expression of the a5 integrin subunit which, with the b1 integrin subunit, forms the a5b1 FN receptor (Supplemental Fig. 2(S) ). HB-EGF was increased in conditioned media from human chondrocytes cultured overnight in the presence of FN-f but not in cells treated with the anabolic growth factor OP-1 [ Fig. 2(B) ].
HB-EGF promotes MMP-13 production, but is not required for fibronectin fragment induced MMP-13 production
After showing that HB-EGF is increased in OA cartilage and that its expression and release by chondrocytes is stimulated by FN-f, we measured the effect of HB-EGF on production of MMP-13, a collagen degrading enzyme that plays a key role in cartilage destruction in OA 16e18 . We stimulated chondrocytes with 10e100 ng/ml HB-EGF and found that doses of 50 and 100 ng/mL were able to stimulate chondrocyte MMP-13 production [ Fig. 3(A) ]. HB-EGF signals through the EGF receptor and in a recent study we found that EGF receptor ligands enhanced FN-f stimulation of MMP-13 production 19 . We therefore tested the effect of low dose HB-EGF co-stimulation on FN-f mediated MMP-13 production. At 10 ng/mL, HB-EGF increased FN-f mediated MMP-13 production [ Fig. 3(B) ]. This effect was blocked when cells were pretreated with the EGF receptor inhibitor AG1478 [ Fig. 3(C) ]. We had previously shown 19 that AG1478 did not block FN-f induction of MMP-13 indicating that HB-EGF but not FN-f signals through the EGFR to stimulate MMP-13 production.
A recent report has indicated that HB-EGF can up-regulate a5b1 integrin expression in intestinal epithelial cells 20 and this integrin is required for matrix degrading effects of FN-f 21 . We treated chondrocytes with HB-EGF for 0.5, 1, 3, and 6 h and found that a5 integrin expression was significantly increased at 3 and 6 h [ Fig. 4(A) ]. We next determined if HB-EGF was required for FN-f mediated MMP-13 production. We transfected chondrocytes with siRNA to silence HB-EGF expression and then stimulated with FN-f. Silencing of HB-EGF had no effect on FN-f mediated MMP-13 expression [ Fig. 4(B) ] despite a significant reduction in HB-EGF expression [ Fig. 4(C) ]. Together, these results suggest that HB-EGF can promote FN-f mediated MMP-13 production and a5b1 expression but HB-EGF is not required for FN-f stimulation of MMP-13 expression.
HB-EGF inhibits anabolic signaling mediated by OP-1
We also tested for a potential anti-anabolic activity of HB-EGF. Reports have indicated that EGF signaling can inhibit bone morphogenetic protein (BMP) signaling through mitogen activated protein (MAP) kinase-mediated phosphorylation of Smad1 at inhibitory serine residues, including serine 206, present in the Smad1 linker region 22 . We therefore sought to determine if HB-EGF could lead to phosphorylation of this inhibitory region on Smad1 and to determine the role of MAP kinases in this process. Smad1 phosphorylation at the inhibitory serine 206 was seen with HB-EGF and HB-EGF plus OP-1 but not OP-1 alone [ Fig. 5(A) ]. HB-EGF did not stimulate phosphorylation of the activating site, which is at serine 463/465 present in Smads1 and 5, and 465/467 in Smad8, and did not alter the ability of OP-1 to stimulate the active site serines. Treatment of chondrocytes for 30 min with 10 ng/mL HB-EGF stimulated phosphorylation of both the ERK and p38 MAP kinases [ Fig. 5(B) ]. The inhibitory Smad1 serine 206 phosphorylation noted with HB-EGF was modestly reduced with inhibition of ERK but not p38, and was completely blocked when both p38 and ERK were inhibited at the same time, suggesting that both MAP kinases contributed to HB-EGF induced Smad1 serine 206 phosphorylation [ Fig. 5(C) ].
Having shown that HB-EGF can phosphorylate inhibitory residues on Smad1, we determined the effect of HB-EGF treatment on BMP mediated anabolic effects in chondrocytes. We stimulated chondrocytes with 100 ng/mL OP-1 (BMP-7) overnight, either with or without co-treatment with 10 ng/mL HB-EGF, and measured the synthesis of proteoglycans using sulfate incorporation. OP-1 stimulated proteoglycan synthesis was inhibited in the presence of HB-EGF (Fig. 6 ). This suggests that HB-EGF can antagonize chondrocyte anabolic signaling mediated by OP-1. Proteoglycan synthesis in cultures treated with HB-EGF alone did not differ from untreated Chondrocytes were stimulated for 30 min with 10 ng/mL HB-EGF. Cell lysates were immunoblotted with antibodies against phosphorylated (P) and total (T) ERK and p38. Results are representative of experiments with cells from four independent donors. (C) Chondrocytes were pretreated for 30 min with either 10 mM U0126 (ERK inhibitor), 10 mM SB203580 (p38 inhibitor), or the combination of the two prior to stimulation with 10 ng/mL HB-EGF for 30 min. Cell lysates were immunoblotted with antibodies against Smad1 phosphorylated on serine206 and total Smad1. Results are representative of three independent donors. Fig. 6 . HB-EGF inhibits OP-1 mediated proteoglycan synthesis. Chondrocytes were stimulated overnight with 100 ng/mL OP-1 or the combination of OP-1 and 10 ng/mL HB-EGF. Proteoglycan synthesis was measured using [ 35 S]sulfate incorporation and DNA was analyzed with a PicoGreen assay. Results were normalized to unstimulated controls set as one and are mean ± sem of four independent donors. controls, indicating HB-EGF does not inhibit basal proteoglycan synthesis (data not shown).
Finally, we examined the effect of HB-EGF on OP-1 mediated gene expression. HB-EGF inhibited OP-1 stimulation of aggrecan expression but did not alter expression of COL2A1 [ Fig. 7(A) and (B)]. We also examined expression of ID1 and SMAD6 which are two BMP target genes but did not detect an effect of HB-EGF on the ability of OP-1 to upregulate these genes [ Fig. 7 (C) and (D)]. Therefore, the inhibitory effects of HB-EGF, at the 10 ng/ml dose tested, appeared to be limited to OP-1 stimulation of aggrecan expression and proteoglycan synthesis suggesting a different mechanism of regulation from COL2A1, ID1, and SMAD6 or that higher amounts of HB-EGF would be needed to inhibit these genes.
Discussion
Using results from a prior gene array study to identify potential contributors to the development of OA, we found that the EGF receptor ligand HB-EGF is present in OA cartilage and is expressed by OA chondrocytes. Production of HB-EGF by normal chondrocytes was stimulated by FN-f, a catabolic stimulus, and promoted FN-f stimulation of MMP-13 production. HB-EGF was also found to have anti-anabolic properties through stimulation of Smad1 phosphorylation at an inhibitory site and this was associated with inhibition of OP-1 mediated aggrecan expression and proteoglycan synthesis. Thus, increased HB-EGF in OA could contribute to the well characterized imbalance in catabolic and anabolic activity that promotes joint tissue destruction.
Like the other EGFR ligands, HB-EGF is synthesized in a pro-form as a transmembrane protein that is cleaved by proteolytic enzymes including ADAM-10 and -12 and MMP-2, -3, and -9 23 . Increased MMP production by OA chondrocytes could promote HB-EGF release where it would act in an autocrine and paracrine fashion to stimulate EGFR signaling. We found that treatment of chondrocytes with FN-f increased HB-EGF expression and resulted in increased release of HB-EGF into the conditioned media. We have previously shown that FN-f stimulates production of multiple MMPs by chondrocytes including MMP-3 10 and more recently found that they also stimulate meniscal cells to produce MMPs that would be capable of cleaving and releasing HB-EGF 15 .
Although HB-EGF was not required for FN-f stimulation of MMP-13 expression, addition of HB-EGF with FN-f resulted in greater MMP-13 production than FN-f alone. Inhibition of the EGF receptor blocked this effect, consistent with a mechanism involving HB-EGF stimulation of EGF receptor signaling. Because FN-f requires activation of the ERK and p38 MAP kinases to stimulate MMP-13 expression 7,13 , it is possible that HB-EGF, which also activates these pathways through the EGFR, promotes a higher level of signaling resulting in increased MMP-13. The ability of HB-EGF to increase a5 integrin expression could also promote the response to FN-f by increasing the number of receptors for FN-f. A previous study in Vero, A431, and MG63 cells found that HB-EGF could form a complex with the diphtheria toxin receptor-associated protein (DRAP27)/CD9 and the a3b1 integrin but not with a5b1 24 making it unlikely that HB-EGF is directly interacting with the chondrocyte a5b1 integrin.
A role for EGFR-mediated signaling in OA has been previously proposed and the findings to date support a role for EGFR ligands in promoting cartilage catabolic gene expression while inhibiting chondrocyte anabolic activity. Treatment of rabbit articular chondrocytes with EGF was found to increase COX-2 expression and PGE 2 levels and to inhibit collagen expression and proteoglycan synthesis 25 . The EGFR ligand TGFa was shown to be present in OA cartilage and to promote cartilage degradation through increased MMP expression as well as to inhibit expression of Sox-9 and matrix genes 5, 6, 26 . We found that HB-EGF at 10 ng/ml inhibited aggrecan expression but not COL2A1. This finding is similar to a previous study from our lab 9 where we found that activation of the ERK MAP kinase with constitutively active MEK inhibited aggrecan but not COL2A1 expression. Because HB-EGF activates ERK it may Fig. 7 . HB-EGF inhibits OP-1 stimulation of aggrecan but not COL2A1, ID1, or SMAD6 expression. Chondrocytes were treated overnight with control media, 10 ng/ml HB-EGF, 100 ng/ ml OP-1, or the same amounts of HB-EGF þ OP-1. RNA was isolated and used for quantitative PCR with primers for aggrecan (A), COL2A1 (B), ID1 (C), and SMAD6 (D). Results shown are the mean ± sem of samples from four independent donors. represent a similar mechanism for differential regulation of aggrecan and collagen expression. Similar to our findings with HB-EGF, both EGF and TGFa signaling in chondrocytes included activation of the MAP kinases ERK as well as p38 6, 25 . It is possible that the level of activation of ERK and p38 differs among the EGFR ligands resulting in differential effects on gene expression or that there is a dose effect, such that higher doses of HB-EGF would be needed to inhibit COL2A1, ID1, and SMAD6 expression than what are needed to inhibit aggrecan expression.
Further evidence that EGFR signaling can promote OA is provided by studies of mitogen-inducible gene 6 (Mig-6) mice. Mig-6 is a negative regulator of EGFR signaling and deletion of Mig-6 in mice has been used to study the effects of excessive EGFR activity on joint tissues. Mice with systemic deletion of Mig-6 were found to have fibrocartilagenous hyperplasia, excessive osteophyte formation and early onset OA that was evident by 3 months of age 27 . Cartilage specific deletion of Mig-6 in floxed mice using Col2a1Cre also resulted in early-onset OA in knee joints after an initial thickening of the cartilage due to excessive chondrocyte proliferation 28 . Of potential relevance to our finding of HB-EGF in the meniscus, Mig-6 was also found to be expressed in the meniscus and deletion in the meniscus appeared to contribute to the development of knee OA 28 .
HB-EGF is expressed in vascular tissues and mice with a deletion of HB-EGF were noted to die soon after birth due to defects in heart and lung development 29 . Of interest to our results showing HB-EGF inhibition of chondrocyte OP-1 signaling, lack of HB-EGF in mice resulted in excessive Smad1/5/8 activation in heart valves, suggesting that HB-EGF serves as a negative regulator of BMP signaling. We noted prominent HB-EGF staining in blood vessel walls in the vascular region of the meniscus consistent with its known expression by endothelial cells which can be promoted by VEGF 30 . A recent study also found HB-EGF to be expressed at higher levels in inflamed areas of synovium compared to normal/reactive areas from patients undergoing knee replacement for OA 31 .
Further studies will be needed to measure the amounts of HB-EGF present in normal and OA cartilage and to clarify the role of HB-EGF in joint tissues in vivo. Because mice with a general deletion of HB-EGF die at a very young age, tissue specific deletion will be necessary to examine the role of HB-EGF in mice. Based on the present findings and on studies to date with other EGFR ligands, as well as with overactivation of EGFR signaling in mice with the Mig-6 deletion, we expect that excessive production of HB-EGF in joint tissues will contribute to OA through altering the balance of chondrocyte anabolic and catabolic activity.
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